Detailed financial statements for Reviva Pharmaceuticals Holdings, Inc. (RVPH): income statement, balance sheet and cash-flow summary. Track margins, debt, liquidity and profitability trends year over year with up to 20 years of history.
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases.
Analysis Summary
Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.
At the current price of $0.49, RVPH has negative trailing earnings (P/E not meaningful) and an ROE of -64.39%. Market capitalisation stands at $6M.
Balance sheet quality for RVPH: current ratio of 2.1, net cash position of $14.0M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Income Statement (10y)
| Year | 2019 | 2020 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | $724740 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | -$724740 | 0 | 0 | 0 | 0 | 0 |
| Research & Development | $946301 | $195744 | $295150 | $4.9M | $18.9M | $31.4M | $22.9M | $11.7M |
| Selling, General & Admin | $175579 | $181116 | $2.1M | $5.3M | $5.4M | $8.1M | $7.9M | $8.5M |
| Operating Expenses | $1.1M | $376860 | $2.4M | $10.1M | $24.3M | $39.5M | $30.8M | $20.2M |
| Operating Income | -$1.1M | -$376860 | -$2.4M | -$10.1M | -$24.3M | -$39.5M | -$30.8M | -$20.2M |
| EBITDA | -$1.1M | -$376014 | -$2.3M | -$10.1M | -$24.1M | -$39.2M | -$29.9M | -$19.8M |
| Interest Expense | $557675 | $469373 | $1.5M | $2414 | $182802 | $33725 | $18497 | $13402 |
| Pre-tax Income | -$1.7M | -$846032 | -$3.8M | -$8.5M | -$24.3M | -$39.2M | -$29.9M | -$19.8M |
| Income Tax | $800 | $800 | $800 | $6004 | $20777 | $16949 | $19514 | $18889 |
| Net Income | -$1.7M | -$846832 | -$3.8M | -$8.5M | -$24.3M | -$39.3M | -$29.9M | -$19.9M |
| EPS | $-16.48 | $-6.20 | $-24.80 | $-11.60 | $-29.00 | $-33.00 | $-18.00 | $-5.48 |
| EPS (Diluted) | $-16.48 | $-6.20 | $-24.80 | $-11.60 | $-29.00 | $-33.00 | $-18.00 | $-5.48 |
| Shares Outstanding (Diluted) | $101984 | $138531 | $153084 | $739542 | $975824 | $1.2M | $1.7M | $3.6M |
Balance Sheet (10y)
| Year | 2019 | 2020 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 0 | $193 | $8.8M | $29.7M | $18.5M | $23.4M | $13.5M | $14.4M |
| Short-term Investments | $65.2M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $65.2M | $193 | $8.8M | $31.4M | $18.9M | $23.7M | $14.7M | $15.1M |
| Property, Plant & Equipment | 0 | $591 | 0 | 0 | 0 | 0 | 0 | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $65.2M | $2600 | $8.8M | $31.4M | $18.9M | $23.7M | $15.5M | $15.9M |
| Accounts Payable | 0 | $224543 | $1.0M | $509583 | $3.5M | $3.8M | $6.3M | $3.0M |
| Short-term Debt | 0 | $3.8M | 0 | 0 | 0 | 0 | $458154 | $406875 |
| Total Current Liabilities | 0 | $100102 | $1.3M | $2.3M | $10.0M | $17.2M | $14.6M | $7.3M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $6.1M | $6.8M | $3.3M | $2.7M | $10.5M | $18.0M | $14.7M | $7.3M |
| Retained Earnings | 0 | -$54.5M | -$58.3M | -$66.8M | -$95.1M | -$134.4M | -$164.3M | -$184.1M |
| Total Equity | 0 | -$6.8M | $5.5M | $28.7M | $8.4M | $5.7M | $812572 | $8.6M |
| Total Debt | 0 | $3.8M | 0 | 0 | 0 | 0 | $458154 | $406875 |
| Net Debt | -$65.2M | $3.8M | -$8.8M | -$29.7M | -$18.5M | -$23.4M | -$13.0M | -$14.0M |
| Working Capital | $65.2M | -$99909 | $7.4M | $29.1M | $9.0M | $6.5M | $81861 | $7.8M |
Cash Flow (10y)
| Year | 2019 | 2020 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$1.7M | -$846832 | -$3.8M | -$8.5M | -$24.3M | -$39.3M | -$29.9M | -$19.9M |
| Depreciation & Amortization | $17718 | $645 | $591 | 0 | 0 | 0 | 0 | 0 |
| Stock-based Compensation | $21054 | 0 | 0 | $106713 | $176735 | $3.4M | $1.6M | $2.2M |
| Change in Working Capital | $541979 | $634152 | -$2.3M | -$702173 | $8.9M | $7.3M | -$4.5M | -$6.9M |
| Operating Cash Flow | -$1.1M | -$218444 | -$4.1M | -$10.7M | -$19.0M | -$28.3M | -$33.5M | -$24.6M |
| Capital Expenditure | 0 | 0 | 0 | 0 | 0 | $3 | -$4 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free Cash Flow | -$1.1M | -$218444 | -$4.1M | -$10.7M | -$19.0M | -$28.3M | -$33.5M | -$24.6M |
Growth & Margins (10y)
| Year | 2019 | 2020 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Net Income Growth (YoY) | +49.6% | -346.8% | -125.2% | -185.6% | -61.3% | +23.8% | +33.6% | |
| EPS Growth (YoY) | +62.4% | -300.0% | +53.2% | -150.0% | -13.8% | +45.5% | +69.6% | |
| Shares Change (YoY) | +35.8% | +10.5% | +383.1% | +31.9% | +21.9% | +39.3% | +118.9% | |
| FCF Growth (YoY) | +79.6% | -1761.6% | -162.3% | -77.7% | -49.4% | -18.4% | +26.7% | |
| Effective Tax Rate | -0.0% | -0.1% | -0.0% | -0.1% | -0.1% | -0.0% | -0.1% | -0.1% |
Per-Share Data (10y)
| Year | 2019 | 2020 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| FCF Per Share | $-10.51 | $-1.58 | $-26.56 | $-14.43 | $-19.43 | $-23.80 | $-20.24 | $-6.78 |
| Dividends Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares Outstanding (Basic) | $101984 | $138531 | $153084 | $739542 | $975824 | $1.2M | $1.7M | $3.6M |
What to look at in Biotech
Most small biotechs lose money. Analysing them with P/E makes no sense — look at cash and pipeline.
- Cash Runway — Months of cash at current burn rate. <18 months = urgent dilution risk
- Annual cash burn — Rate at which they burn operating cash. Compare with cash position to project runway
- Total Debt — Biotech with no revenue + debt = recipe for bankruptcy
- R&D / Market cap — How much they invest in pipeline vs the company value — research-intensity indicator
- Market cap / Cash — If it trades near its cash, the market assigns ~0 value to the pipeline — opportunity or trap
Profitability
| Return on Equity | -64.39% |
| Return on Invested Capital | -17.05% |
| Return on Assets | -11.58% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Debt / Equity | 0.01 |
| Current Ratio | 3.56 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -18.12 |
Key Ratios (10y)
| Year | 2019 | 2020 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| P/E | -12.21 | -34.06 | -7.05 | -4.98 | -2.93 | -3.12 | -2.01 | -1.02 |
| P/B | 0.00 | -4.30 | 4.90 | 1.49 | 9.88 | 21.43 | 73.84 | 2.34 |
| P/S | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Related companies: ANVS · ATNM · BCAB · BTAI · CELU · EVAX · FGEN
Explore sector: Healthcare · Biotechnology
More sections of RVPH: Overview · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks